Cboe CA - Delayed Quote ? CAD Cybin Inc. (CYBN.NE) Follow Compare 15.70 +1.38 (+9.64%) At close: October 18 at 3:59 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 TORONTO, October 03, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in the Water Tower Research Fireside Chat Series taking place on Tuesday, October 8, 2024, at 3:00 p.m. ET. Business Wire ? 17 days ago CYBN +9.19% Cybin Expands Clinical Team to Support CYB003 Phase 3 Program TORONTO, October 01, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the appointment of senior clinical team leaders, Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez, Vice President, Clinical Pharmacology, as well as the expan Business Wire ? 19 days ago CYBN +9.19% Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit TORONTO, September 24, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin’s Chief Medical Officer, will participate in a panel discussion at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually on September 26, 2024. Business Wire ? 26 days ago CYBN +9.19% Cybin Provides Corporate Update on Upcoming Clinical Milestones TORONTO, September 19, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones. Business Wire ? last month CYBN +9.19% Cybin Announces Completion of Previously Announced Share Consolidation TORONTO, September 19, 2024--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of amendment to consolidate the Company’s issued and outstanding common shares (the "Common Shares") on the basis of one new Common Share for every 38 existing Common Shares (t Business Wire ? last month CYBN +9.19% Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference TORONTO, September 04, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat and panel at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New Business Wire ? last month CYBN +9.19% Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation TORONTO, August 27, 2024--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on August 27, 2024 (the "Meeting"). There were 87 shareholders represented in person or b Business Wire ? last month CYBN +9.19% Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder TORONTO, August 13, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it held a Type B Initial Breakthrough Therapy Meeting with the U.S. Food and Drug Administration ("FDA") late last week in Washington, D.C. The Company plans to initiate its Phase 3 pivotal trial of CYB003 for Business Wire ? 2 months ago CYBN +9.19% Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights TORONTO, August 08, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2024, and recent business highlights. Business Wire ? 2 months ago CYBN +9.19% Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference TORONTO, August 07, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, taking place August 13-14, 2024 in Boston, MA. Business Wire ? 2 months ago CYBN +9.19% A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser, Cybin highlighted key advancements that strengthened its position as a leader in developing next-generation psychedelic-based therapeutics. Included is evidence that this Toronto-based clinical-stage biopharmaceutical compan Newsfile ? 3 months ago CYBN +9.19% What Makes Cybin Inc. (CYBN) a New Buy Stock Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks ? 3 months ago CYBN +9.19% Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights TORONTO, June 26, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental health disorders, today reported audited financial results for its fiscal year ended March 31, 2024, and recent business highlights. Business Wire ? 3 months ago CYBN +9.19% Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference TORONTO, June 19, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, taking place June 27, 2024. Business Wire ? 3 months ago CYBN +9.19% Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Zacks ? 4 months ago CYBN +9.19% Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development TORONTO, June 11, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, has joined the Company as Senior Vice President, Clinical Development. Dr. Mahableshwarkar will lead the development of the CYB003 program, Cybin’s proprie Business Wire ? 4 months ago CYBN +9.19% Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 TORONTO, May 29, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin’s Chief Medical Officer, and Ellen James, Ph.D., Cybin’s Director, Clinical Development, will participate at the Interdisciplinary Conference on Psychedelic Res Business Wire ? 4 months ago CYBN +9.19% Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase TORONTO, May 14, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2024. Business Wire ? 5 months ago CYBN +9.19% Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones TORONTO, May 06, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline. Business Wire ? 5 months ago CYBN +9.19% Cybin to Participate at the 27th Annual Milken Institute Global Conference TORONTO, April 25, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled "Collaborating for Improved Mental Health." The Conference will Business Wire ? 5 months ago CYBN +9.19% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is MSCI WORLD Return CYBN.NE MSCI WORLD YTD -22.05% +18.39% 1-Year -35.44% +34.42% 3-Year -83.07% +19.20%
